WE EXPECT THEM TO BE THE BEST 
PEOPLE WE CAN REALLY HAVE AND 
ALL MEMBER STATES WILL BE 
INVOLVED IN CONTRIBUTING TO THE 
PANEL MEMBERS OF CANDIDATES.  
OF COURSE, IT WILL BE UP TO THE 
COCHAIRS COINCIDED WITH ME TO 
SELECT THE MEMBERS.  
I THINK THAT WILL ALSO 
HOPEFULLY HELP US IN BALANCING 
THE CAPACITY OF THE PANEL 
ITSELF AND THERE WOULD BE AN 
INDEPENDENCE GREATER IT.  
WE'RE NOT GOING TO USE W.H.O. 
SECRETARY I CAN'T THINK ATE 
MEAN WE WILL HAVE ADDITIONAL 
MANPOWER BUT NOT ONLY THE 
INDEPENDENT SECRETARIATE.  
AS THE IT'S ALSO OUR CONCERN 
THAT THE MEET THE EVALUATION IN 
THE MIDDLE OF THE RESPONSE 
COULD HAVE SOME EFFECT.  
BUT WE WILL DO EVERYTHING TO 
BALANCE IT IN ORDER TO LEARN AS 
WE GO.  
THANK YOU.  
. 
>>  THANK YOU DR. TEDROS AND 
DR. RYAN.  
OUR NEXT QUESTION COMES FROM 
ANTONIO BERTE OF THE SPANISH 
NEWS WIRE.  
AND PLEASE, YOU'RE WELCOME TO 
ASK IN SPANISH IF YOU PREFER.  
PLEASE UNMUTE YOURSELF AND GO 
AHEAD. 
>> GOOD AFTERNOON.  
CAN YOU HEAR ME? 
>> VERY WELL.  
PLEASE GO AHEAD. 
>>  OKAY.  
YES, I WILL MAKE MY QUESTION IN 
ENGLISH  SPANISH IF I MAY.    
[ SPEAKING FOREIGN LANGUAGE ]   
>> OUR ADVICE HAS BEEN QUITE 
CONSISTENT IN ADVISING 
COUNTRIES TO NUMBER ONE OPEN UP 
SLOWLY IN A STEPWISE FASHION. 
AND TO WAIT BETWEEN DIFFERENT 
PHASES OF REOPENING AND TO 
ENSURE THE DATA ON THE VIRUS IS 
CLEAN AND CLEAR AND TELLS US 
WHERE YOU ARE AND TO BE READY 
TO MOVE BACKWARDS OR FORWARDS 
DEPENDING ON WHAT THE DATA IS 
TELLING YOU AND TO ACCEPT THE 
FACT THAT IN OUR CURRENT 
SITUATION IT IS VERY UNLIKELY 
THAT WE CAN ERADICATE OR 
ELIMINATE THIS VIRUS THAT ARE 
VERY PARTICULAR ENVIRONMENTS 
WHICH THAT CAN OCCUR BUT EVEN 
THEY RISK REIMPORTATION. 
WE HAVE SEEN COUNTRIES MANAGE 
TO GET TO ZERO OR ALMOST 0 
MANAGED TO REIMPORT AND SAID 
THERE IS EITHER RISK FROM 
WITHIN OR WITHOUT AND THERE IS 
A GIVEN THERE IS ALWAYS A RISK 
OF FURTHER CASES THE 
TRANSMISSION THAT OCCURS IN 
THAT SITUATION CAN BE SINGLE, 
SPORADIC CASES WHICH CAN BE 
RELATIVELY EASILY ISOLATED AND 
QUARANTINED. 
AND MORE WORRYING PATTERN IS 
LARGE CLUSTERS OF CASES THAT 
COULD OCCUR IN ASSOCIATION WITH 
SUPER SPREADING EVENTS WITH 
LARGE CROWDS GATHERED AND THE 
VIRUS IS PRESENT AND YOU GET A 
SMALL EXPLOSION OF CASES WHICH 
CAN VERY QUICKLY MUSHROOM INTO 
MUCH LARGER CASES. 
VERY ANALOGOUS TO A FOREST 
FIRE. 
A SMALL FIRE IS HARD TO SEE BUT 
EASY TO PUT OUT GOOD A LARGE 
FIRE IS EASY TO SEE THAT VERY 
DIFFICULT TO PUT OUT. 
YOU REALLY NEED A SYSTEM WHERE 
YOU CAN DETECT THE SMALL FLAMES 
IN THE SMALL EMBERS THAT MAY BE 
THEY ARE AND YOU CAN DETECT 
THAT SMALL FIRE AND PUT IT OUT 
BY GOOD SURVEILLANCE, GOOD 
DETECTION AND AGGRESSIVE 
TESTING AND BY ISOLATING CASES, 
QUARANTINING CASES THROUGH ALL 
OF THIS, AND I THINK THIS IS A 
VERY CENTRAL MESSAGE, THAT WHEN 
THE VIRUS IS PRESENT THERE IS 
RISK OF SPREAD AND AUTHORITIES 
CAN HAVE SURVEILLANCE IN PLACE 
AND ALL OF THOSE MEASURES WITH 
TESTING BUT IT COMES DOWN TO 
COMMUNITIES AND INDIVIDUALS AND 
HOW WE PROTECT OURSELVES AND 
OTHERS. 
WHEN THE VIRUS IS IN YOUR 
COMMUNITY IT IS QUITE CLEAR 
THERE ARE THINGS YOU AND YOUR 
COMMUNITY COULD DO TO REDUCE 
THE RISK OF THOSE INFECTIONS 
AND IT IS IMPORTANT THAT PEOPLE 
FEEL EMPWERED AND THEY HAVE 
THE KNOWLEDGE TO BE ABLE TO DO 
THAT. 
IT REQUIRES A VERY STRONG 
PARTNERSHIP, A TRUSTING 
PARTNERSHIP BETWEEN COMMUNITIES 
AND AUTHORITIES, A TRUSTING 
PARTNERSHIP BASED ON HONESTY 
AND TRANSPARENCY AND REGULAR 
INFORMATION EVERYONE CAN TRUST 
AND BASED ON A SUSTAINED EFFORT 
BY EVERYBODY. 
IT IS A VERY TOUGH RIGHT NOW 
FOR EVERYONE TO MAINTAIN THE 
KIND OF VIGILANCE PEOPLE ARE 
BEING ASKED TO MAINTAIN. 
IT IS NOT EASY. 
BUT WE HAVE TO BE ABLE TO 
SUSTAIN THAT. 
IF WE WANT TO AVOID AFTER A 
LOCKDOWN HAVING MAJOR EPIDEMIC 
WE NEED TO WATCH OUT FOR THE 
SMALL CLUSTERS AND WE NEED TO 
EXTINGUISH THOSE CLUSTERS 
QUICKLY. 
WE ALL NEED TO REMAIN VIGILANT. 
REMAIN VIGILANT WITH OUR 
PHYSICAL DISTANCING, OUR 
HYGIENE AND MASKS AND 
APPROPRIATE SETTINGS AND IN 
THAT SITUATION WE CAN 
POTENTIALLY AVOID THE WORST OF 
HAVING SECOND PEAKS AND HAVING 
TO MOVE BACKWARDS IN TERMS OF 
LOCKDOWN. 
AND YOU HAVE SEEN THIS IN A 
NUMBER OF COUNTRIES, MANAGING 
TO DEAL WITH CLUSTERS AND 
FLAREUPS BY HAVING LIMITED 
GEOGRAPHIC LOCKDOWNS, LOCKING 
DOWN SMALL AREAS IN ORDER TO 
CONTAIN THE DISEASE. 
IT IS A MATTER OF SCALE I 
THINK. 
COUNTRIES CAN AND SHOULD BE 
ABLE TO CONTAIN THE DISEASE 
WITH THIS MEASURES. 
WE WANT TO AVOID WHOLE 
COUNTRIES GOING BACK INTO TOTAL 
LOCKDOWN AND IT IS NOT A DESIRE 
ANYBODY HAS BUT THERE MAY BE 
SITUATIONS IN WHICH IT IS THE 
ONLY OPTION. 
THIS IS A FUNDAMENTAL QUESTION 
FOR EVERYONE, EVERY COMMUNITY 
AND EVERY SOCIETY. 
IT IS GOING TO REQUIRE 
SUSTAINED EFFORT AND IT WILL 
REQUIRE A LOT OF TRUST AND IT 
WILL REQUIRE CLEAR MESSAGING 
AND A HUGE INVESTMENT OF 
SUSTAINED PUBLIC HEALTH EFFORT 
AND A MASSIVE INVESTMENT IN 
COMMUNITY EMPOWERMENT AND THE 
CAPACITY OF US AS INDIVIDUALS 
WITHIN OUR COMMUNITIES TO ACT 
AND STAY SAFE.>> THANK YOU. 
AS MIKE SAID I THINK THIS IS 
SOMETHING WE ALL NEED TO 
ANTICIPATE THAT THERE IS A 
POSSIBILITY OF A RESURGENCE AND 
SMALL OUTBREAKS. 
BUT I THINK WHAT WE HAVE BEEN 
ADVISING IS IN THESE SITUATIONS 
IS TO ACT FAST AND ACT 
COMPREHENSIVELY USE THE PUBLIC 
HEALTH INFRASTRUCTURE YOU HAVE 
IN PLACE AND MANY COUNTRIES 
HAVE WORKED INCREDIBLY HARD TO 
IMPROVE THE INFRASTRUCTURE IN 
PLACE AND TO BE ABLE TO FIND 
TEST CASES AND ISOLATE CASES 
VERY QUICKLY. 
IF THEY HAVE SYMPTOMS AND IF 
THEY DEVELOP DISEASE TO ENSURE 
THEY ARE CARE FOR APPROPRIATELY 
AND IN THE APPROPRIATE 
FACILITIES. 
TO PUT CONTACT TRACING TO THE 
TEST AND CARRY OUT CONTACT 
TRACING AS COMPREHENSIVELY AS 
POSSIBLE, QUARANTINING THE 
CONTACTS THE BREAK THE CHAINS 
OF TRANSMISSION. 
AND INFORM THE COMMUNITIES 
OFTEN AND REGULARLY AND 
HONESTLY AND THOROUGHLY BECAUSE 
THE SITUATION IS EVOLVING AND 
WE KNOW HOW QUICKLY THESE 
EMBERS CAN TURN INTO FOREST 
FIRES. 
AND WITH THAT HOPE THAT IF 
RESTRICTIONS ARE PUT IN PLACE 
THEY ARE PUT IN PLACE 
TEMPORARILY AND THEY PUT IN 
PLACE IN A LIMITED GEOGRAPHIC 
REGION ONLY TO HELP AND THEY 
ARE NOT PUT IN PLACE FOR LONG 
TIME FRAMES. 
BUT IT IS POSSIBLE THESE SMALL 
OUTBREAKS AND SMALL CLUSTERS 
CAN BE PREVENTED FROM TURNING 
INTO LARGE OUTBREAKS AND WE 
HAVE SEEN IT TIME AND TIME 
AGAIN SO IT IS POSSIBLE. 
AS MIKE HAS SAID AND AS WE HAVE 
SAID BE A PART OF THE RESPONSE. 
EVERYBODY HAS A ROLE TO PLAY 
AND IF YOU'RE ASKED TO STAY 
HOME AND YOU CAN'T SAY HOME 
PLEASE DO AND IF YOU'RE FEELING 
UNWELL TO STAY HOME AND CALL 
THE HOTLINE TO FIND OUT THE 
NEXT STEPS YOU NEED TO TAKE 
BECAUSE EVERYBODY NEEDS TO PLAY 
A PART. 
IT WILL TAKE TIME AS WE TAKE 
TIME TO FIGURE OUT HOW TO GET 
THROUGH IT TOGETHER BUT IT IS 
TO BE EXPECTED. 
YET WE HAVE TOOLS IN PLACE AND 
GOVERNMENTS HAVE WORKED 
INCREDIBLY HARD AND COMMUNITIES 
HAVE WORKED VERY HARD AND 
INDIVIDUALS HAVE WORKED VERY 
HARD SO WE NEED TO PUT THOSE 
TOOLS IN USE AGAIN.>> THANK YOU 
DOCTORS. 
THE NEXT QUESTION COMES FROM 
THE SHANGHAI MEDIA GROUP, IF 
YOU WISH TO ASK YOUR QUESTION 
IN CHINESE WE HAVE THE 
TRANSLATION SERVICE SO PLEASE 
DO.>> THANK YOU. 
I WILL CONTINUE ASKING MY 
QUESTION IN ENGLISH AND I THANK 
YOU FOR TAKING IT. 
IT IS IN FOLLOW-UP IN REGARDING 
THE INDEPENDENT PANEL AND WE 
CURRENTLY KNOW THAT THE PANEL 
IS SELECTED AND THEY CAN CHOOSE 
OTHER PANEL MEMBERS SO HOW MANY 
MORE PANEL MEMBERS WILL BE 
SELECTED AND ITS AREAS OF 
EXPERTISE LIKE POLICYMAKERS OR 
MEDICAL PROFESSIONALS OR 
SPECIALISTS IN PUBLIC HEALTH? 
THANK YOU. 
>> YEAH THANK YOU. 
SO THE SIZE OF THE PANEL, THERE 
WAS DISCUSSION OF COURSE BUT 
NOT YET DECIDED BUT THE 
COCHAIRS WILL DECIDE AS THEY 
SEE FIT. 
IN THE PANEL MEMBERS OF COURSE 
WILL BE A MIX OF PROFESSIONALS. 
AGAIN THIS WILL BE UP TO THE 
COCHAIRS BASED ON TERMS OF 
DIFFERENCE TO SELECT PEOPLE WHO 
REALLY FIT INTO TERMS OF 
REFERENCE. 
THESE ARE THINGS THAT WILL BE 
DONE ONCE THE COCHAIRS START 
ACTUALLY WORKING ON THIS 
ASSIGNMENT. 
THANK YOU.>> THE NEXT QUESTION 
COMES FROM JACQUELINE HOWARD OF 
CNN, PLEASE UNMUTE YOURSELF AND 
GO AHEAD.>> THANK YOU FOR 
TAKING MY QUESTION. 
WE HAVE NOTICED REPORTS 
CIRCULATING ABOUT A PNEUMONIA 
AND KAZAKHSTAN THAT MAY BE 
QUOTE DEADLIER THAN COVID WHICH 
IS WHAT SOME OF THESE REPORTS 
ARE SAYING. 
I WANTED TO ASK IF THIS IS 
SOMETHIG THAT W.H.O. 
IS INVESTIGATING OR CAN THERE 
BE ANY MORE INFORMATION SHARED  
ABOUT WHETHER THESE REPORTS ARE 
ACCURATE OR WHETHER THIS IS 
SOMETHING ON YOUR RADAR. 
THANK YOU.>> YES IT IS 
CERTAINLY ON OUR RADAR AND WE 
HAVE BEEN TRACKING COVID 19 
ACROSS ALL OF EUROPE AND IN 
PARTICULAR CENTRAL ASIAN 
REPUBLICS INCLUDING KAZAKHSTAN. 
ON JULY 5, PATRICK STAN WENT 
BACK INTO A LOCKDOWN AS COVID 
19 CASES SPIKED IN THE FIRST 
LOCKDOWN WAS FROM MARCH 16 
UNTIL MAY 11. 
THE SECOND LOCKDOWN IS TO LAST 
TWO WEEKS. 
AS OF JULY 7 WE HAVE JUST UNDER 
50,000 CASES OF WHAT HAS BEEN 
REPORTED AND THERE ARE A NUMBER 
OF EXPLANATIONS THAT CAN 
EXPLAIN THE REPORT OF THE RISE 
IN THE NUMBER OF PNEUMONIAS AND 
KAZAKHSTAN AND WE ARE WORKING 
WITH AUTHORITIES THERE TO 
INVESTIGATE. 
MORE THAN 10,000 LIBERATORY 
FROM CASES OF COVID 19 CASES OF 
BEEN REPORTED BY NATIONAL 
AUTHORITIES OVER THE LAST SEVEN 
DAYS SO THERE'S BEEN A SURGE IN 
ACTUAL COVID CASES ITSELF. 
WE ARE LOOKING AT THE ACTUAL 
QUALITY OF THE TESTING TO MAKE 
SURE THEY'RE NOT BEEN FALSE 
NEGATIVE TEST FOR SOME OF THE 
OTHER PNEUMONIAS THAT WERE 
PROVISIONALLY TESTED NEGATIVE 
AND THAT IS LIKELY TO BE A 
MAJOR CAUSE AND THAT IN MANY 
WAYS MANY OF THESE PNEUMONIA 
CASES WILL ALSO BE COVID 19 AND 
NOT DIAGNOSED CORRECTLY. 
BUT IT REMAINS TO BE SEEN. 
WE ARE WORKING WITH AUTHORITIES 
TO LOOK AT X-RAYS AND REVIEW 
THEM AND LOOK AT THE PATTERNS 
OF THE PNEUMONIAS TO MAKE SURE 
THEY ARE CONSISTENT WITH COVID 
19. 
WHY WOULD BELIEVE THAT MANY OF 
THESE CASES WILL BE DIAGNOSED 
AS COVID 19 WE KEEP AN OPEN 
MIND AND WERE WORKING CLOSELY 
WITH THE AUTHORITIES TO TRACK 
THIS AND ENSURE THAT IS THE 
CASE. 
IT CAN BE CAUSED BY DISEASES AS 
WIDE-RANGING AS LEGIONELLA, 
CHLAMYDIA, INFLUENZA AND OTHER 
THINGS TO THEIR POTENTIAL OTHER 
CAUSES FOR CLUSTERS OF ATYPICAL 
úPNEUMONIA AND WE KEEP AN OPEN 
MIND AND TO HAVE DEFINITIVE 
DIAGNOSIS. 
BUT THE UPWARD TRAJECTORY OF 
COVID 19 CASES IN THE COUNTRY 
WOULD SUGGEST THAT MANY OF 
THESE CASES ARE IN FACT 
UNDIAGNOSED CASES OF COVID 19. 
AS I SAID WE KEEP AN OPEN MIND 
UNTIL THERE IS ABSOLUTE 
CONFIRMATION OF DIAGNOSIS OF 
THESE CLUSTERS.>> THANK YOU AND 
NOW I HAVE A QUESTION FROM 
HELEN BRANDT WHILE. 
PLEASE GO AHEAD. 
>> THANK YOU FOR TAKING MY 
QUESTION. 
MIKE COULD YOU GIVE AN UPDATE 
ON THE OUTBREAK IN THE ECUADOR 
PROVINCE? 
THANK YOU.>> YES WHAT I WILL DO 
IS PERHAPS PASS TO ANOTHER 
QUESTION AND I WILL COME BACK 
ON THAT BECAUSE I WANT TO GIVE 
NUMBERS, IT IS A NUMBERS PERSON 
AND I CAN GIVE A GENERAL ANSWER 
AND GIVE YOU MORE SPECIFIC 
NUMBERS IN A FEW MINUTES. 
HELEN YOU'RE AT THE END OF THE 
CUBE THAT WE WILL COME BACK TO 
YOU. 
THIS NEXT IS FROM NHK JAPAN. 
PLEASE UNMUTE YOURSELF AND GO 
AHEAD.>> CAN YOU HEAR ME? 
>> VERY WELL.>> THANK YOU. 
MY QUESTION IS REGARDING 
AIRBORNE TRANSMISSION. 
ACCORDING TO THE SCIENCE 
RELEASED YESTERDAY AIRBORNE 
TRANSMISSION OF THE VIRUS CAN 
OCCUR IN HEALTHCARE SETTINGS AND
SOME OF AND/OR IN CROWDED 
SPACES HAVE SUGGESTED THE 
POSSIBILITY OF AEROSOL 
TRANSMISSION AND BASED ON THE 
EVIDENCE YOU HAVE SO FAR DO YOU 
RECOGNIZE AIRBORNE TRANSMISSION 
IS A REALISTIC DANGER IN OUR 
DAILY LIVES AND WHAT IS YOUR 
RECOMMENDATION TO THE GENERAL 
PUBLIC?>> THANK YOU FOR THE 
QUESTION AND YES YOU HAVE 
HIGHLIGHTED A SCIENTIFIC 
BRIEFLY PUBLISHED YESTERDAY ON 
TRANSMISSION OF COVID 19 AND 
THE SARS VIRUS THAT CAUSES 
OVID 19 AND IN THE SCIENTIFIC 
BRIEF IT IS NOT A GUIDANCE 
DOCUMENT BUT A BRIEF WHICH 
SUMMARIZES ALL AVAILABLE 
LITERATURE AND EVIDENCE WE HAVE 
ON HOW THE VIRUS IS TRANSMITTED 
WHEN IT TRANSMITS BETWEEN 
PEOPLE AS IT RELATES TO THEIR 
INFECTION AND WHAT IT MEANS IN 
TERMS OF BREAKING CHAINS OF 
TRANSMISSION. 
WE LOOK AT DROPLET AND AEROSOL 
WE LOOK AT FECAL AND ORAL AND 
LOTS OF DIFFERENT MODES. 
OUR ATTEMPTS TO DO THIS IS 
CONSOLIDATING WHAT WE KNOW 
ABOUT THE VIRUS AND THERE IS 
NEW LITERATURE BEING PUBLISHED 
AT LEAST EVERY SINGLE DAY SO 
THIS IS A LIVING REVIEW WHAT WE 
CALL IT A LIVING REVIEW WHICH 
MEANS IT WILL BE UPDATED 
REGULARLY AND WITHIN THE 
BRIEFLY TALK ABOUT DROPLET AND 
AEROSOL IN YOUR SPECIFIC 
QUESTION IS ABOUT AEROSOL 
TRANSMISSION. 
IT IS ONE OF THE MODES OF 
TRANSMISSION WE HAVE BEEN 
CONCERNED ABOUT SINCE THE 
BEGINNING PARTICULARLY IN 
HEALTHCARE SETTINGS AND THERE 
ARE MEDICAL PROCEDURES CALLED 
AEROSOL GENERATING PROCEDURES 
WHERE WE KNOW THE DROPLETS CAN 
BE AEROSOLIZED WHICH MEANS THE 
PARTICLES COULD STAY SUSPENDED 
AN AREA FOR LONGER TIME. 
IN THOSE SITUATIONS WHERE THE 
HEALTH WORKER IS CARRYING OUT 
THOSE PROCEDURES AND FOR THOSE 
WORKING IN THOSE AREAS WE 
RECOMMEND AIRBORNE PRECAUTIONS 
WHICH IS A CERTAIN TYPE OF 
PERSONAL PROTECTIVE EQUIPMENT 
FOR HEALTH WORKERS AND OUTSIDE 
OF HEALTH SETTINGS THERE IS A 
POSSIBILITY THERE COULD BE 
AEROSOLIZED PARTICLES IN 
SPECIFIC SETTINGS LIKE INDOOR 
SETTINGS WHERE THERE ARE 
CROWDED CONDITIONS AND WHERE 
THERE IS POOR VENTILATION AND 
WHERE PEOPLE ARE SPENDING 
PROLONGED TIME FRAMES. 
WHAT WE HAVE SEEN IS THERE ARE 
SOME OUTBREAKS THAT HAVE BEEN 
REPORTED IN THESE CLOSED INDOOR 
SETTINGS WITH POOR VENTILATION 
WHICH INCLUDE WHAT YOU HAD 
MENTIONED, THE NIGHTCLUBS AND 
CHOIRS, FITNESS CENTERS, WHERE 
AIRBORNE TRANSMISSION COULD NOT 
BE RULED OUT. 
IN THOSE OUTBREAKS THAT COULD 
BE DROPLET TRANSMISSION AND 
CONTAMINATED SURFACE 
TRANSMISSIONS. 
WHAT WE ARE CALLING FOR IS MORE 
SYSTEMATIC RESEARCH TO BE DONE 
IN THESE TYPES OF SETTINGS SO 
IT IS NOT JUST HOW AND WHEN 
TRANSMISSION HAPPENS BUT THE 
SETTINGS IN WHICH THEY HAPPEN 
SO WE NEED A BETTER 
UNDERSTANDING OF THESE 
PARTICULAR SETTINGS AND THE 
OUTBREAKS HAPPENING SO WE CAN 
BETTER UNDERSTAND HOW 
TRANSMISSION IS HAPPENING. 
IN TERMS OF EVERYDAY LIFE WE 
RECOMMEND A COMPREHENSIVE SET 
OF PACKAGES WHICH INCLUDE 
PHYSICAL DISTANCING WHICH DOES 
INCLUDE HAND HYGIENE AND 
RESPIRATORY ETIQUETTE AND IT 
INCLUDES THE USE OF FABRIC 
MASKS WHEN YOU CANNOT DO 
PHYSICAL DISTANCING. 
AND TO ENSURE THAT WHEN YOU 
HAVE THESE CLOSE SETTINGS YOU 
HAVE GOOD VENTILATION SO IT IS 
A COMBINATION OF PACKAGES THE 
DOMINANT ROUTES OF TRANSMISSION 
FROM ALL OF THE AVAILABLE 
EVIDENCE AND OUR UNDERSTANDING 
WORKING WITH LARGE GROUPS OF 
DIFFERENT DISCIPLINES, IS 
DROPLET AND CONTACT ALTHOUGH 
THERE MAY BE OTHER MODES OF 
TRANSMISSION WHICH WE DO NOT 
RULE OUT. 
SO WE HAVE REQUESTED AND 
THROUGH OUR BLUEPRINTS WHICH WE 
BEGAN WORKING ON SINCE 
FEBRUARY, IS TO ACCELERATE 
RESEARCH IN THE AREA AND TO 
MAKE SURE THAT WE HAVE WELL 
CONDUCTED STUDIES SO WE COULD 
BETTER DETERMINE THE DIFFERENT 
ROLES OF TRANSMISSION AND SO 
THAT ALL OF THE ADVICE WE GIVE 
IS AS UP-TO-DATE AS POSSIBLE.>> 
THANK YOU. 
NOW A QUESTION FROM SIMON FROM 
TODAY NEWS AFRICA WHICH I 
UNDERSTAND HAS A BURNING 
QUESTION ABOUT SMOKING IN 
COVID. 
PLEASE GO AHEAD.>> THANK YOU 
FOR TAKING MY QUESTION. 
MY FIRST QUESTION,  I AM 
WONDERING IF W.H.O. 
KNOWS HOW THE VIRUS  AFFECTS 
PREGNANT WOMEN AND IF AND HOW 
IT AFFECTS BABIES, AND IF THERE 
IS A CORRELATION BETWEEN COVID 
19 AND SMOKING AND IF SMOKING 
MAKES IT WORSE.>> PERHAPS I 
COULD START WITH SMOKING. 
GOOD AFTERNOON. 
WE KNOW THAT IF YOU ARE A 
SMOKER THE LIKELIHOOD OF 
DEVELOPING MORE SEVERE SYMPTOMS 
FOR COVID ARE HIGHER. 
WE KNOW THAT THE WAY THAT YOU 
CAN ATTRACT COVID IS NOT YET 
ESTABLISHED WHAT YOU CAN SAY IS 
IF YOU ARE A SMOKER THAT YOU 
SHOULD STOP SMOKING STRAIGHT 
AWAY BECAUSE OF LIKELIHOOD OF 
HAVING MORE SEVERE SYMPTOMS>> 
DO WE TAKE THE SECOND QUESTION? 
YOU SNUCK WHEN IN. 
SO THANK YOU FOR THE QUESTION 
ABOUT COVID 19 AND PREGNANT 
WOMEN. 
AND OF COURSE WE ARE ALWAYS 
CONCERNED ABOUT COVID 19 IN ANY 
POPULATION AND IN PARTICULAR 
PREGNANT WOMEN. 
WHAT WE UNDERSTAND FROM THIS IS 
THE CLINICAL MANAGEMENT TEAM 
LOOKS CLOSELY AT THIS AND 
WITHIN CLINICAL GUIDANCE 
SPECIFIC RECOMMENDATIONS FOR 
PREGNANT WOMEN. 
WE UNDERSTAND THAT AMONG WOMEN 
WHO ARE PREGNANT THEY DO NOT 
SEEM TO DEVELOP A DIFFERENT 
TYPE OF DISEASE FROM WOMEN OF 
THE SAME AGE THAT ARE NOT 
PREGNANT BUT THERE ARE STUDIES 
THAT COME OUT RECENTLY THAT 
HAVE LOOKED AT REGNANT WOMEN 
WITH UNDERLYING CONDITIONS. 
AND IF THERE ARE WOMEN WITH 
UNDERLYING CONDITIONS THEY ARE 
AT HIGHER RISK OF DEVELOPING 
MORE SEVERE DISEASE. 
THIS IS SOMETHING THAT WE NEED 
TO ENSURE WE KEEP A CLOSE EYE 
ON AND ENSURE THAT PREGNANT 
WOMEN HAVE THE RIGHT CLEAR 
THROUGH THEIR PREGNANCIES.>> 
THANK YOU. 
NOW HAVE ANOTHER QUESTION CAN 
YOU HEAR ME MARGARET?>> YES. 
>> THANK YOU. 
WE HAVE SEEN THE PAST FEW DAYS 
THE PRESIDENT AND MY QUESTION 
TO YOU DID ANYTHING CHANGE IN 
THESE STUDIES OR ARE YOU STILL 
STICKING TO THE POINT THAT THIS 
DRUG AT LEAST SO FAR HASN'T 
SHOWN ANY KIND OF EVIDENCE IN 
TERMS OF SCIENCE. 
WHAT IS YOUR POSITION IN TERMS 
OF TAKING QUARANTINE, NOT TO 
REDUCE MEDICAL HOSPITALIZED 
DAYS BUT AS THE PRESIDENT IS 
TAKING AT THIS MOMENT, THANK 
YOU.
>> IT IS DIFFICULT TO COMMENT 
ON THE SPECIFIC USE OF HYDRO 
CLOCKS HE OR HYDROXY 
CHLOROQUINE AND IT SHOULD BE 
USED IN THE CONTEXT OF COVID 
ONLY UNDER STRICT MEDICAL 
SUPERVISION AND WE WOULD ASSUME 
THAT IS THE CASE IN THIS CASE. 
THE FINDINGS REGARDING 
HYDROXYCHLOROQUINE FOR 
HOSPITALIZED PATIENTS DO NOT 
DEMONSTRATE DIFFERENCES IN 
MORTALITY ALTHOUGH THERE ARE 
LOTS OF DIFFERENT STUDIES THAT 
ARE OUT THERE AND AT PRESENT, 
W.H.O.  
DOES NOT HAVE USE OF THIS IN 
HOSPITALIZED PATIENTS ON THE 
BASIS THE DRUG HAS NOT CLEARLY 
DEMONSTRATED THE BENEFITS TO 
THOSE WHO TAKE IT. 
AND THAT IS FOR INDIVIDUAL 
CLINICIANS TO MAKE 
DETERMINATIONS REGARDING THE 
USE OF THE DRUG ON AND OFF 
LABEL BASIS. 
WE CAN ONLY REPORT WHAT WE SEE 
FROM RANDOMIZED CONTROLLED 
TRIALS AND OTHER OBSERVATIONAL 
THAT IS. 
IN THE END IT IS FOR NATIONAL 
AUTHORITIES TO DETERMINE ABOUT 
THE USE OF THE DRUG IN THE 
CONTEXT IT IS OBVIOUSLY FOR THE 
USE FOR INDIVIDUAL CLINICIANS 
TO DECIDE ON HOW TO USE THAT 
KNOWLEDGE. 
>> I HAVE A QUESTION FROM 
GABRIELLA SODA MAYOR PLEASE 
UNMUTE YOURSELF AND GO AHEAD.>> 
[ FOREIGN LANGUAGE BEING SPOKEN 
] 
>> IT IS DIFFICULT TO PREDICT 
THE TRAJECTORY OF ANY EPIDEMIC 
IN COUNTRIES AT THE MOMENT BUT 
MEXICO NOW HAS THE FIFTH 
HIGHEST COVID 19 DEATH TOLL AND 
HAS HAD RECORD-BREAKING DAYS IN 
THE LAST WEEK OF RECORDING 
NEARLY 70,000 CASES IN A SINGLE 
DAY BUT IT'S TOTAL CASE IS NOW 
SURPASSING A QUARTER OF 1 
MILLION. 
MEXICO AT THE SAME TIME IS IN 
THE PROCESS OF REOPENING AND IN 
THIS THE NUMBER OF CASES HAS 
INCREASED SIGNIFICANTLY AND IT 
IS A PATTERN WE HAVE SEEN IN 
MANY OTHER COUNTRIES OPENING 
ECONOMIES IN THE MIDST OF 
INTENSE COMMUNITY TRANSMISSION 
CAN LEAD TO AN ACCELERATION OF 
CASES WHICH IS NOT UNIQUE AT 
ALL TO THE MEXICAN SITUATION. 
IN MEXICO LIKE OTHER COUNTRIES 
IS BALANCING THE DEMANDS OF 
COMMUNITIES TO GET BACK TO WORK 
AND TO BE ABLE TO EARN LIVINGS 
WITH A SIGNIFICANT RISK OF 
INCREASED AND INTENSIFIED AND 
ACCELERATED COVID TRANSMISSION. 
AND SO I THINK FROM THE 
PERSPECTIVE OF MEXICO AND OTHER 
COUNTRIES IN THIS SITUATION, 
THEY MAY FACE A CONTINUED 
INCREASE IN CASES OVER TIME 
BECAUSE AS I SAID IN PREVIOUS 
INTERVENTION TODAY THAT IF THE 
VIRUS IS PRESENT AND 
TRANSMITTING EFFICIENTLY A 
COMMUNITY LEVEL AND COMMUNITIES 
CONTINUE TO MIX AND ENGAGE IN 
NORMAL ACTIVITY AND PUBLIC 
HEALTH SURVEILLANCE IS WEAK IN 
THAT SITUATION AND THERE'S NOT 
THE ABILITY TO IDENTIFY CASES 
QUICKLY, IF THESE DO NOT WORK 
IN CONCERT TOGETHER AND IF YOU 
REACH THE POINT WHERE THE 
NUMBER OF CASES EXCEEDS THE 
CAPACITY OF THE PUBLIC HEALTH 
SYSTEM TO CHASE DOWN CONTEXT 
AND CASES AND IT EXCEEDS 
CAPACITY OF THE HEALTH SYSTEM 
TO COPE WITH SEVERE CASES WE'RE 
RIGHT BACK WHERE WE STARTED IN 
FEBRUARY AND MARCH WITH SYSTEMS 
EFFECTIVELY FAILING THE FACE OF 
THE PRESSURE OF THE NUMBER OF 
INFECTED. 
WE NEED TO TRY TO AVOID THAT. 
AND AGAIN THE QUESTION IN THE 
COUNTRY THAT IS THE SIZE OF 
MEXICO AND MANY OTHER COUNTRIES 
LIKE IT IS LOCATED ON A 
NATIONAL LEVEL AT THE WHERE THE 
VIRUS IS UNDER CONTROL AND 
WHERE WE CONTINUE TO UNDERSTAND 
WHAT HOTSPOTS ARE AND WE MAY 
HAVE TO SLOW DOWN OR REVERSE 
PARTS OF THAT REOPENING AND 
INTENSIFY COMMUNICATIONS WITH 
COMMUNITIES. 
AND AGAIN IT COMES DOWN TO A 
CERTAIN EXTENT TO TRUST, THERE 
MUST BE CONSISTENT AND CLEAR 
MESSAGING ON RISK FROM 
AUTHORITIES AND LEADERS WE MUST 
BE HONEST WITH OUR COMMUNITIES 
ABOUT THE SPREAD OF THE DISEASE 
IN OUR COMMUNITIES AND WE MUST 
COMMUNICATE THE RISK 
APPROPRIATELY. 
WE MUST GIVE PEOPLE THE 
INFORMATION THEY NEED TO 
MAINTAIN PROPER SOCIAL DISTANCE 
AND TO ENGAGE IN PROPER 
PERSONAL HYGIENE AND WEAR MASKS 
WHERE APPROPRIATE WE MUST 
SUPPORT OUR COMMUNITIES AND 
DOING THAT AND CONSISTENTLY 
MESSAGE THAT IN AN APPROPRIATE 
WAY. 
AGAIN IT IS DIFFICULT FOR 
COUNTRIES, ESPECIALLY WHEN THE 
INDIVIDUAL ECONOMIC 
CONSEQUENCES TO INDIVIDUAL 
FAMILIES ARE NEGATIVE AND YOU 
CANNOT GO TO WORK AND YOU 
CANNOT EARN MONEY AND YOU 
CANNOT FEED YOUR FAMILY THERE 
IS A HUGE CONSEQUENCE AND WE 
FULLY UNDERSTAND THE PRESSURES 
THAT THE PEOPLE THEMSELVES ARE 
UNDER AND WE FULLY UNDERSTAND 
FROM THAT THE PRESSURES THAT 
GOVERNMENTS ARE UNDER BUT WE 
HAVE TO FIND A WAY TO BALANCE 
THESE TWO IMPORTANT ISSUES AND 
HAVE TO FIND A WAY TO BALANCE 
THE COVID 19 ACCELERATION 
AGAINST THE ECONOMIC REOPENING 
BECAUSE IT IS VERY CLEAR FROM A 
NUMBER OF COUNTRIES THAT 
OPENING IN THIS SITUATION WHERE 
YOU HAVE INTENSE COMMUNITY 
TRANSMISSION AND A WEAK PUBLIC 
HEALTH RESPONSE LEADS TO A 
DIFFICULT SITUATION THAT MAY 
PUSH A WHOLE COUNTRY BACK IN 
TERMS OF THE PROGRESS IT MAKES. 
AND THAT IS NOT 
INCONSEQUENTIAL. 
AND BLIND REOPENING, NOT 
ASSOCIATE WITH A CAREFUL 
STEPWISE PROCESS BASED ON DATA 
AND OPEN COMMUNICATION, IT MAY 
NOT LEAD TO WHERE ANYBODY 
WISHES TO GO IN ANY COUNTRY, 
MEXICO INCLUDED.>> THANK YOU 
DOCTOR RYAN, THE NEXT QUESTION 
IS ON COVID AND SUCKING AND 
THIS COMES FROM JIM GROUP. 
PLEASE GO AHEAD. 
>> HELLO AND THANK YOU AS I 
LOOK TO THIS QUESTION AS I TYPE 
TO YOU I WOULD BE HAPPY IF YOU 
JUST PASS IT ALONG YOURSELF AND 
I APPRECIATE IT BUT IT IS ONE 
OF THOSE STUPID QUESTIONS 
BECAUSE THE ANSWER IS OBVIOUS 
BUT I'LL ASK ANYWAY. 
THE QUESTION WAS WITH COVID 19 
AND SMOKING, HER ROYAL HIGHNESS 
SAID PEOPLE WHO SMOKE ARE MORE 
LIKELY TO CONTRACT THE VIRUS 
AND ALSO MORE LIKELY TO SPREAD. 
SO I QUESTION IS WHAT IS THE 
SPREADING ASPECT OF IT AND IS 
IT BECAUSE THE VIRUS CAN LINGER 
IN SMOKE OR IS IT BECAUSE OF 
THE EXHALE FACTOR OR BECAUSE 
THE SMOKER IS NOT WEARING A 
MASK? 
I REALIZE IT IS PROBABLY ALL OF 
THE ABOVE AND IF I'M WRONG, AND 
THE ANSWER ISN'T THEN MIKE YOU 
COULD ANSWER.
>> I CAN TAKE THAT. 
AS I SAID IT LEADS TO MORE 
SEVERE DISEASE AND THAT IS THE 
MAIN CAUSE. 
THAT IS WHY AT THE MOMENT WE 
KNOW THAT 618 MILLION PEOPLE 
WANT TO QUIT SMOKING AND WE 
KNOW THAT 400 MILLION IS THE 
LATEST ESTIMATE THAT WILL TRY 
TO STOP SMOKING. 
THAT IS THE GOOD NEWS. 
WITH TODAY'S INITIATIVE WE HOPE 
THAT WE WILL BE SUCCESSFUL IN 
HELPING 20 MILLION TO SUCCEED 
IN THIS. 
THAT THEY ARE THE FINAL 
ESTIMATES WE HAVE.
>> THANK YOU. PLEASE GO AHEAD 
WITH THE NEXT QUESTION.>> THANK 
YOU MY QUESTION HAS BEEN ASKED 
TO LET ME USE THE CHANCE TO ASK 
ABOUT HOW THE WAY FORWARD IS 
LOOKING IN TERMS OF TREATMENTS. 
OBVIOUSLY HAVE SOME NEGATIVE 
RESULTS ON SOME EXPERIMENTAL 
TREATMENTS. 
IS IT BECOMING CLEARER THE NEXT 
ONES ARE THAT NEED TO BE 
TESTED? 
BECAUSE I THINK WE'RE GETTING 
TO THAT SECOND PHASE.>> I CAN 
START AND PERHAPS MIKE WOULD 
LIKE TO SUPPLEMENT ON THIS 
BECAUSE IT IS A BIG QUESTION 
HAT YOU ASKED AND A GOO 
WHAT I CAN SAY IS WITHIN OUR 
CLINICAL MANAGEMENT NETWORK AND 
WITHIN THE R&D GROUP THERE ARE 
A NUMBER OF THERAPEUTICS AND 
DRUGS CURRENTLY UNDER 
EVALUATION AND THOSE CLINICAL 
TRIALS ARE UNDERWAY THEIR SMALL 
TRIALS AND OF COURSE THE 
SOLIDARITY TRIAL IS UNDERWAY. 
WHAT THE CLINICAL NETWORK IS 
DOING AND WITH R&D PARTNERS IS 
WORKING WITH THOSE THAT ARE 
CARRYING OUT THOSE CLINICAL 
TRIALS AND TO FOLLOW THEM IN 
REAL TIME BECAUSE MANY OF THEM 
ARE SMALL AND THERE ARE 
POSSIBILITIES THAT WE COULD TRY 
TO DEFINE THE DATA COMING IN 
FROM THE STUDIES SO WE CAN GET 
A QUICKER ANSWER TO THESE 
QUESTIONS. 
I DO NOT HAVE ANY SPECIFICS ON 
WHICH ONE IS THE NEXT ONE, THAT 
IS THE TRILLION DOLLAR QUESTION 
HERE, BUT I THINK THERE ARE A 
NUMBER OF THERAPEUTICS THAT ARE 
INTERESTING THAT WILL COVER 
DIFFERENT ASPECTS OF THE 
DISEASE, WHETHER THEY ARE THE 
PREVENTION OF DEVELOPING MORE 
SEVERE DISEASE OR PREVENTING 
PEOPLE FROM DYING. 
A LOT ARE CURRENTLY UNDERWAY 
AND THERE ARE HUGE NUMBER 
CLINICAL TRIALS. 
MIKE YOU WANT TO ADD 
ANYTHING?>> NO. 
I THINK YOU HAVE SAID IT ALL. 
I THINK THE CLINICIANS THAT 
CAME TOGETHER LAST WEEK HAD 
ESSENTIALLY THE SAME VIEW AND 
THERE ARE LOTS OF EXISTIN 
THERAPIES WE HAVE SEEN AND SOME 
DATA THAT THERE ARE EXISTING 
THERAPIES FOR OTHER DISEASES 
MAY HAVE IMPACT. 
WE WILL CONTINUE TO FIND 
POTENTIAL TREATMENTS AND THE 
DRUGS WE ALREADY HAVE AND JUST 
BEING ABLE TO PICK THE BEST OF 
THOSE CANDIDATES AND BRING THEM 
INTO THE SOLIDARITY IS 
IMPORTANT AND THAT IS WHY THE 
SOLIDARITY AND RECOVERY AND 
DISCOVERY TRIALS WERE DESIGNED 
AS MULTI-ARMS. 
THEY ALLOW US WITH OTHER 
PARTNERS ACROSS MANY COUNTRIES 
TO BRING THIS INTO THAT ARMORY 
OF POTENTIAL DRUG. 
THE BIGGER QUESTION IS NEW 
MOLECULES AND NEW DRUGS BEING 
DISCOVERED BECAUSE THEY 
OBVIOUSLY HAVE A MUCH LONGER 
PATHWAY TO BE USED IN HUMANS 
AND THE ADVANTAGE YOU HAVE WITH 
EXISTING DRUGS AS MANY OF THEM 
HAVE STRONG SAFETY PROFILES AND 
ARE APPROVED FOR OTHER DISEASES 
AND THEY COULD BE RELATIVELY 
EASILY INTRODUCED IN RANDOMIZED 
CONTROL TRIALS. 
WE HAVE A SAFETY PROFILE FOR 
THOSE DRUGS. 
OTHER DRUGS OR NEW MOLECULES 
THAT HAVE TO BE DEVELOPED HAVE 
TO GO THROUGH THE WHOLE RIGOR 
OF SCIENTIFIC SAFETY, SCOPE AND 
PROCESS THAT TAKES LONGER TO 
BRING THOSE DRUGS INTO 
RANDOMIZED CONTROLLED TRIALS 
BECAUSE THEY HAVE TO GO THROUGH 
PRIMARY SAFETY STUDIES FIRST. 
THAT SLOWS DOWN THE PROCESS BY 
WHICH THE MOLECULES ARE 
AVAILABLE BUT THERE ARE MANY, 
MANY OF THOSE MOLECULES THAT 
ARE CURRENTLY AVAILABLE AND 
OTHER TREATMENTS ARE CLEARLY 
ALREADY BEING USED. 
WE HAVE ANTIBODIES THAT SHOW 
GREAT HOPE. 
WE DO USE THEM TO GOOD EFFECT 
IN EBOLA. 
I THINK THEY HAVE BEEN 
GROUNDBREAKING IN REDUCING 
MORTALITY AND HIGHLY SUCCESSFUL 
IN REDUCING FATALITY AND 
TRANSFORM THE WAY WE MANAGE 
EBOLA AS A DISEASE. 
I THINK THERE ARE POTENTIAL 
PLATFORMS AND TYPES OF DRUGS 
THAT MAY RESULT IN A MUCH 
FASTER WAY TO GET THOSE TALL 
PEOPLE WHO NEED THEM. 
BUT AGAIN IT IS A COMPLEX AREA 
AND WE ARE VERY VERY PLEASED 
WITH THE LEVEL OF COLLABORATION 
BETWEEN INSTITUTES, CLINICIANS, 
HOSPITALS AND EVERY DIFFERENT 
KIND OF PHYSICIAN, DOCTOR OR 
NURSING ORGANIZATION THAT WE 
HAVE SEEN TODAY. 
WE HAVE SEEN OTHER FANTASTIC 
CARDIOVASCULAR IMPACTS AND WHAT 
WE ARE SEEING IS ONE OF THE 
FASTEST ACCELERATIONS OF 
KNOWLEDGE. 
THAT IN ITSELF IS PROVIDING 
VERY INTERESTING INSIGHTS FOR 
WHAT WE ARE TREATING SO WHEN WE 
LOOK AT OTHER DRUGS AND TRIALS, 
WE CAN ATTACK THE VIRUS IN TWO 
WAYS, ONE BY TREATING THE VIRUS 
AND IN THAT SENSE TRYING TO USE 
DRUGS THAT WILL IMPEDE THE 
VIRUS CAPACITY TO HURT US BUT 
WE CAN ALSO TREAT THE IMPACT ON 
THE VIRUS BY MODULATING THE 
IMMUNE RESPONSE TO THE VIRUS IN 
CERTAIN STAGES WHICH PREVENTS 
OUR SYSTEMS FROM OVERREACTING 
AND DAMPENING THE INFORMATION. 
AND WE CAN LOOK AT VARIOUS 
OTHER INTERVENTIONS AND WAY 
LIKE STATINS AND OTHER DRUGS 
THAT MAY PREVENT BLOOD CLOTTING 
AND SO WE HAVE TO MANAGE THE 
VIRUS ITSELF, TREAT THE VIRUS 
ITSELF, OR THE CONSEQUENCES OF 
HAVING THE VIRUS. 
THERE IS A TREMENDOUS AMOUNT OF 
WORK TO DO THAT AND BEFORE WE 
UNDERSTAND THE DISEASE IT HAS, 
I'M HOPEFUL IN TERMS OF THE 
LEVELS OF COLLABORATION AND 
LEVELS OF INNOVATION AND WE ARE 
CONFIDENT THAT WE WILL FIND 
THERAPIES OVER TIME WHICH BODES 
WELL FOR THE FUTURE OF EMERGING 
DISEASES IN GENERAL. 
AND IN GENERAL FOR OUR ABILITY 
TO COLLECTIVELY COLLECTED AND 
ONE OF THE IMPORTANT THINGS IS 
TO GAIN UNDERSTANDING OF HOW 
THE VIRUS OR DISEASE OPERATES 
IN THE HUMAN BODY AND 
UNDERSTAND HOW IT IMPACTS HUMAN 
ORGANS AND HOW IT SPREADS AND 
IT AFFECTS THE IMMUNE SYSTEM. 
THE MORE WE UNDERSTAND THAT THE 
MORE RAPID WE UNDERSTAND THAT, 
IT IS THE SPACE OR 
PHARMACOLOGICAL SIDE OF THINGS 
WE CAN DEVELOP THOSE MEASURES. 
WHILE WE ARE DESPERATELY 
NEEDING MORE THERAPIES I 
BELIEVE THE WORLD PROBABLY THIS 
POINT COULD NOT BE DONE MORE 
COLLECTIVELY.>> TO GIVE A 
SPECIFIC EXAMPLE OF THIS 
SCIENCE SOLUTION AND SOLIDARITY 
IS ONE OF THE THINGS WERE 
LOOKING INTO, DOCTOR JANET DIAZ 
MENTIONED IT THE OTHER DAY, IS 
TRYING TO OPERATE A NEW MODEL 
OF WORKING TOGETHER, AND WE'VE 
REACHED OUT TO A NUMBER OF PIS 
WORKING ON SPECIFIC THERAPEUTIC 
FOR EXAMPLE SO THEY CAN WORK 
WITH US ON A PERSPECTIVE 
ANALYSIS WHERE THEY AGREE TO 
SHARE DATA ON THEIR INDIVIDUAL 
TRIALS AND THEN WE CAN PULL 
THIS AND WE DO THESE ANALYSES 
AS THE TRIALS ARE STILL GOING. 
SO WE'RE LEARNING AND WE'RE 
ABLE TO UNDERSTAND HOW THESE 
THERAPIES WORK SO WHEN WE NEED 
TO ADAPT GUIDANCE, IF WE NEED 
TO ADAPT GUIDANCE, THAT CAN BE 
DONE HERE AND THAT IS A NEW 
MODEL OF WORKING. 
AND AGAIN AS MIKE HAS SAID THIS 
IS AN INCREDIBLE SOLIDARITY AND 
COLLABORATION TO BE ABLE TO 
AGREE TO SHARE THIS AS THE 
TRIALS ARE ONGOING BUT IT IS 
SOMETHING WE'RE TRYING ARE 
WORKING VERY HARD TO DO WE'RE 
VERY GRATEFUL FOR THOSE WHO 
HAVE AGREED TO DO THIS WITH 
US.>> THANK YOU.
>> WE WILL TAKE YOU TO FLORIDA 
NOW WHERE PRESIDENT TRUMP IS 
RECEIVING AID BRIEFING ON DRUG 
TRAFFICKING SO LET'S TAKE A 
LISTEN.>> LEADERS AND MILITARY 
GENIUSES AND PEOPLE WHO DO A 
FANTASTIC JOB. 
JUST 12 WEEKS THE SURGE 
OPERATIO
